Removal of Entry from the Australian Register of Therapeutic Goods - Concept Laboratories Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate therapeutic goods within the country, ensuring their safety, quality, and efficacy. The Act establishes a framework for the regulation of therapeutic goods, including medicines, medical devices, and other related products, and empowers the Therapeutic Goods Administration (TGA) to implement and enforce these regulations. One of the objectives of the Act is to maintain and enhance public health and safety by ensuring that only safe and effective therapeutic goods are available to the public. In this context, the Act provides mechanisms for the inclusion and exclusion of goods from the Australian Register of Therapeutic Goods (ARTG), which is a key component of the regulatory framework. In this particular instance, the Therapeutic Goods Administration, as a delegate of the Secretary of the Department of Health, exercised its authority under section 9F of the Therapeutic Goods Act 1989 to remove the entry of a specific product from the ARTG. The product in question, Germbuster Anti-bacterial Hand Gel, manufactured by Concept Laboratories Pty Ltd, was removed from the ARTG due to the Secretary’s satisfaction that the product does not meet the criteria for classification as a therapeutic good. This action aims to uphold the integrity of the ARTG and ensure that only goods that genuinely contribute to public health and safety are included in the register.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, and its scope encompasses the regulation of goods through registration and licensing processes, as well as the ability to remove entries from the Australian Register of Therapeutic Goods (ARTG) when necessary. In this instance, the Act applies to the removal of a specific product, Germbuster Anti-bacterial Hand Gel, from the ARTG, illustrating its application to therapeutic goods and their sponsors. The decision to remove the product was made by a delegate of the Secretary of the Department of Health under section 9F of the Act, indicating the Commonwealth's jurisdictional reach. The Act applies to the goods themselves, their sponsor, Concept Laboratories Pty Ltd, and the therapeutic nature of the goods. There are no exclusions, exemptions, or thresholds specified in this particular decision, and the Act extends its application through subordinate instruments, which may include regulations and guidelines that provide further detail on the processes and criteria for registering or delisting therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989, in particular section 9F, outlines the process by which entries can be removed from the Australian Register of Therapeutic Goods (ARTG). This section was invoked by a delegate of the Secretary of the Department of Health to remove the entry for "Germbuster Anti-bacterial Hand Gel" from the ARTG. This decision was made on 6 October 2015 and became effective on 17 November 2015. The product, listed under ARTG number 121546 and sponsored by Concept Laboratories Pty Ltd, was removed because the Secretary was satisfied that it did not qualify as a therapeutic good. Under the Therapeutic Goods Act 1989, the removal of an entry from the ARTG signifies that the goods in question do not meet the legislative criteria for being classified as therapeutic goods. This can include products that fail to demonstrate efficacy, safety, or quality as required by the Act. When a product is removed from the ARTG, it is no longer legally permitted to be marketed as a therapeutic good in Australia. This action is a regulatory tool used to ensure that only products meeting specific standards are available to consumers. Entities affected by the removal of their product from the ARTG, such as Concept Laboratories Pty Ltd, are required to comply with the decision and cease marketing the product as a therapeutic good. Sponsors must also notify relevant stakeholders and consumers about the removal. Additionally, they may be obligated to return or dispose of any remaining stock in accordance with the Act’s provisions. This ensures that the product does not continue to be available on the market under false pretenses. The Therapeutic Goods Act 1989 imposes strict penalties for non-compliance with its provisions. Any person who contravenes the Act by continuing to market a product removed from the ARTG as a therapeutic good may face both civil and criminal penalties. Civil penalties can include substantial fines, up to a maximum of $1.1 million for individuals and $5.5 million for corporations, as stipulated under section 94 of the Act. Additionally, criminal penalties may apply, with fines and imprisonment terms detailed in section 95, reflecting the seriousness of disregarding regulatory decisions designed to protect public health and safety.